Cited 0 times in Scipus Cited Count

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).

DC Field Value Language
dc.contributor.authorLee, SJ-
dc.contributor.authorKim, TM-
dc.contributor.authorKim, YJ-
dc.contributor.authorJang, KT-
dc.contributor.authorLee, HJ-
dc.contributor.authorLee, SN-
dc.contributor.authorAhn, MS-
dc.contributor.authorHwang, IG-
dc.contributor.authorLee, S-
dc.contributor.authorLee, MH-
dc.contributor.authorLee, J-
dc.date.accessioned2017-06-05T05:53:14Z-
dc.date.available2017-06-05T05:53:14Z-
dc.date.issued2015-
dc.identifier.issn1083-7159-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/14033-
dc.description.abstractBACKGROUND: KIT has been suggested to be a potential therapeutic target for malignant melanoma. We evaluated the antitumor activity and safety of the KIT inhibitor nilotinib in metastatic melanoma patients harboring KIT gene mutations or amplifications.

METHODS: We conducted a phase II multicenter trial of nilotinib in metastatic malignant melanoma with KIT mutations or amplifications. Patients received 400 mg oral nilotinib twice daily. The primary endpoint was response rate, and if seven or more responders were observed from the cumulative 36 patients, nilotinib would be considered worthy of further testing in this study population.

RESULTS: Between October 2009 and June 2013, 176 patients underwent molecular screening for KIT gene aberrations, and 42 patients harboring KIT gene mutations and/or amplification were enrolled in the study. Overall, 25 (59.5%), 15 (35.7%), and 2 (4.8%) patients had KIT mutations, KIT amplifications, and both KIT mutations and amplification, respectively. Of the 42 enrolled patients, 1 patient achieved complete response, 6 patients achieved partial response, and 17 patients achieved stable disease, resulting in an overall response rate of 16.7% (95% confidence interval [CI]: 5.4%-28.0%) and a disease control rate of 57.1% (95% CI: 42.1%-72.1%). The median duration of response was 34 weeks (range: 5-55 weeks). Of the 7 responders, 6 patients had KIT mutations (exon 11: 5 patients; exon 17: 1 patient), and 1 patient had KIT amplification only.

CONCLUSION: Although this study did not meet its primary endpoint of response rate, nilotinib showed durable response in a subset of metastatic melanoma patients with specific KIT mutations.

IMPLICATIONS FOR PRACTICE: KIT aberration can be detected in a subset of metastatic melanoma patients. This phase II trial showed that nilotinib demonstrates durable response in a subset of patients with KIT mutations. The safety profile was very tolerable. This study suggests that a KIT inhibitor may benefit a small subset of metastatic melanoma patients with KIT mutations.
-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHAged-
dc.subject.MESHAged, 80 andover-
dc.subject.MESHDisease-Free Survival-
dc.subject.MESHFemale-
dc.subject.MESHGene Amplification-
dc.subject.MESHHumans-
dc.subject.MESHMale-
dc.subject.MESHMelanoma-
dc.subject.MESHMiddle Aged-
dc.subject.MESHMutation-
dc.subject.MESHNeoplasm Metastasis-
dc.subject.MESHProto-Oncogene Proteins c-kit-
dc.subject.MESHPyrimidines-
dc.titlePhase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).-
dc.typeArticle-
dc.identifier.pmid26424760-
dc.identifier.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4718426/-
dc.contributor.affiliatedAuthor안, 미선-
dc.type.localJournal Papers-
dc.identifier.doi10.1634/theoncologist.2015-0161-
dc.citation.titleThe oncologist-
dc.citation.volume20-
dc.citation.number11-
dc.citation.date2015-
dc.citation.startPage1312-
dc.citation.endPage1319-
dc.identifier.bibliographicCitationThe oncologist, 20(11). : 1312-1319, 2015-
dc.identifier.eissn1549-490X-
dc.relation.journalidJ010837159-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Hematology-Oncology
Files in This Item:
26424760.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse